Literature DB >> 25491288

Severe XLP Phenotype Caused by a Novel Intronic Mutation in the SH2D1A Gene.

B Tóth1, B Soltész1, E Gyimesi2, G Csorba1, Á Veres3, Á Lányi3, G Kovács4, L Maródi1, M Erdős5.   

Abstract

We describe here a novel c.137 + 5G > A intronic mutation in the SH2D1A gene of the signaling lymphocyte activation molecule (SLAM)-associated protein (SAP) in association with Epstein-Barr virus (EBV)-induced fatal infectious mononucleosis (FIM) in an 8-year-old male patient and his 3-year-old step brother. The mother and the maternal grandmother of the boys are healthy and heterozygous for this sequence variant. Genetic sequencing of blood-cell-derived cDNA in the younger patient revealed a 22 bp deletion in the SH2D1A cDNA. Immunoblot and flow cytometry analysis performed in this younger patient showed the lack of SAP protein expression in peripheral blood lymphocytes. These data suggest that the novel c.137 + 5G > A mutation results in loss of function of SAP protein and leads to typical X-linked lymphoproliferative disease phenotype. We propose that intron 1 and the c.137 + 5G may be the most frequent intronic hot spot for SH2D1A splicing mutation.

Entities:  

Keywords:  SH2D1A; XLP; novel intronic mutation

Mesh:

Substances:

Year:  2014        PMID: 25491288     DOI: 10.1007/s10875-014-0117-1

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  24 in total

1.  SH2D1A mutation analysis for diagnosis of XLP in typical and atypical patients.

Authors:  L Yin; V Ferrand; M F Lavoué; D Hayoz; N Philippe; G Souillet; M Seri; R Giacchino; E Castagnola; S Hodgson; B S Sylla; G Romeo
Journal:  Hum Genet       Date:  1999-11       Impact factor: 4.132

2.  X-linked lymphoproliferative disease with a novel SH2D1A gene mutation.

Authors:  Marusa Debeljak; Katarina Trebusak Podkrajsek; Richard Aplenc; Janez Jazbec
Journal:  Pediatr Blood Cancer       Date:  2008-01       Impact factor: 3.167

Review 3.  Molecular and immunological basis of X-linked lymphoproliferative disease.

Authors:  Sylvain Latour; André Veillette
Journal:  Immunol Rev       Date:  2003-04       Impact factor: 12.988

4.  Clinical similarities and differences of patients with X-linked lymphoproliferative syndrome type 1 (XLP-1/SAP deficiency) versus type 2 (XLP-2/XIAP deficiency).

Authors:  Jana Pachlopnik Schmid; Danielle Canioni; Despina Moshous; Fabien Touzot; Nizar Mahlaoui; Fabian Hauck; Hirokazu Kanegane; Eduardo Lopez-Granados; Ester Mejstrikova; Isabelle Pellier; Lionel Galicier; Claire Galambrun; Vincent Barlogis; Pierre Bordigoni; Alain Fourmaintraux; Mohamed Hamidou; Alain Dabadie; Françoise Le Deist; Filomeen Haerynck; Marie Ouachée-Chardin; Pierre Rohrlich; Jean-Louis Stephan; Christelle Lenoir; Stéphanie Rigaud; Nathalie Lambert; Michèle Milili; Claudin Schiff; Helen Chapel; Capucine Picard; Geneviève de Saint Basile; Stéphane Blanche; Alain Fischer; Sylvain Latour
Journal:  Blood       Date:  2010-11-30       Impact factor: 22.113

5.  Expansion of functionally immature transitional B cells is associated with human-immunodeficient states characterized by impaired humoral immunity.

Authors:  Amanda K Cuss; Danielle T Avery; Jennifer L Cannons; Li Jun Yu; Kim E Nichols; Peter J Shaw; Stuart G Tangye
Journal:  J Immunol       Date:  2006-02-01       Impact factor: 5.422

Review 6.  X-linked lymphoproliferative syndromes: brothers or distant cousins?

Authors:  Alexandra H Filipovich; Kejian Zhang; Andrew L Snow; Rebecca A Marsh
Journal:  Blood       Date:  2010-07-26       Impact factor: 22.113

7.  Epstein-Barr virus persistence in the absence of conventional memory B cells: IgM+IgD+CD27+ B cells harbor the virus in X-linked lymphoproliferative disease patients.

Authors:  Sridhar Chaganti; Cindy S Ma; Andrew I Bell; Debbie Croom-Carter; Andrew D Hislop; Stuart G Tangye; Alan B Rickinson
Journal:  Blood       Date:  2008-05-28       Impact factor: 22.113

8.  X-linked lymphoproliferative disease. 2B4 molecules displaying inhibitory rather than activating function are responsible for the inability of natural killer cells to kill Epstein-Barr virus-infected cells.

Authors:  S Parolini; C Bottino; M Falco; R Augugliaro; S Giliani; R Franceschini; H D Ochs; H Wolf; J Y Bonnefoy; R Biassoni; L Moretta; L D Notarangelo; A Moretta
Journal:  J Exp Med       Date:  2000-08-07       Impact factor: 14.307

9.  SAP controls the cytolytic activity of CD8+ T cells against EBV-infected cells.

Authors:  Loïc Dupré; Grazia Andolfi; Stuart G Tangye; Rita Clementi; Franco Locatelli; Maurizio Aricò; Alessandro Aiuti; Maria-Grazia Roncarolo
Journal:  Blood       Date:  2005-01-27       Impact factor: 22.113

10.  New and recurrent gain-of-function STAT1 mutations in patients with chronic mucocutaneous candidiasis from Eastern and Central Europe.

Authors:  Beáta Soltész; Beáta Tóth; Nadejda Shabashova; Anastasia Bondarenko; Satoshi Okada; Sophie Cypowyj; Avinash Abhyankar; Gabriella Csorba; Szilvia Taskó; Adrien Katalin Sarkadi; Leonóra Méhes; Pavel Rozsíval; David Neumann; Liudmyla Chernyshova; Zsolt Tulassay; Anne Puel; Jean-Laurent Casanova; Anna Sediva; Jiri Litzman; László Maródi
Journal:  J Med Genet       Date:  2013-05-24       Impact factor: 6.318

View more
  1 in total

1.  Cerebral Vasculitis in X-linked Lymphoproliferative Disease Cured by Matched Unrelated Cord Blood Transplant.

Authors:  Paul E Gray; Tracey A O'Brien; Mayura Wagle; Stuart G Tangye; Umaimainthan Palendira; Tony Roscioli; Sharon Choo; Rosemary Sutton; John B Ziegler; Katie Frith
Journal:  J Clin Immunol       Date:  2015-10-03       Impact factor: 8.317

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.